Study guide
13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal
Key Takeaways Explain This Topic AI
Primary haemostasis produces a temporary platelet plug (defects cause mucocutaneous bleeding and petechiae); secondary haemostasis involves the coagulation cascade to form a fibrin mesh (defects cause deep haematomas and haemarthroses).
Haemophilia A (Factor VIII deficiency) and Haemophilia B (Factor IX deficiency) are X-linked recessive disorders with isolated APTT prolongation; von Willebrand disease is autosomal dominant with mucocutaneous bleeding and defective platelet adhesion.
Thrombotic Thrombocytopenic Purpura (TTP) is caused by ADAMTS13 deficiency producing microangiopathic haemolytic anaemia (schistocytes) and thrombocytopenia; platelet transfusion is strictly contraindicated as it accelerates fatal thrombosis.
Major life-threatening bleeding on warfarin mandates immediate cessation, IV Phytomenadione (Vitamin K1 5–10 mg), and Four-Factor Prothrombin Complex Concentrate (4F-PCC); dabigatran is reversed by Idarucizumab, and Factor Xa inhibitors are reversed by Andexanet alfa or PCC.
Last updated: October 2026
Haemostasis, Coagulation Disorders & Anticoagulant Reversal
Haemostasis is the physiological mechanism that prevents excessive blood loss following vascular disruption while maintaining blood in a fluid state within intact vessels.
1. Physiology of Haemostasis & Coagulation Profile Interpretation
Haemostasis proceeds in two tightly coordinated physiological phases:
Primary Haemostasis (Platelet Plug Formation): Endothelial injury exposes subendothelial collagen. Circulating von Willebrand factor (vWF) binds to exposed collagen, allowing platelet adhesion via the platelet membrane glycoprotein Ib (GpIb) receptor. Adherent platelets activate, undergo conformational shape changes, and secrete chemical mediators (thromboxane A2, ADP) that recruit and activate additional circulating platelets. Platelets aggregate via glycoprotein IIb/IIIa (GpIIb/IIIa) receptors cross-linked by fibrinogen, forming an unstable primary platelet plug. Deficiencies in primary haemostasis cause mucocutaneous bleeding (epistaxis, menorrhagia, gingival bleeding, petechiae, and purpura).
Secondary Haemostasis (Coagulation Cascade): Tissue factor exposed at the injury site activates the extrinsic pathway, leading via Factor X activation to the common pathway. Small amounts of thrombin (Factor IIa) trigger massive feedback amplification of the intrinsic tenase complex (Factors VIIIa, IXa) on the negatively charged platelet membrane surface. Thrombin rapidly cleaves soluble fibrinogen into insoluble fibrin monomers , which are covalently cross-linked by Factor XIIIa into a stable secondary haemostatic fibrin meshwork. Deficiencies in secondary haemostasis cause deep tissue bleeding (haemarthroses, muscle haematomas, and delayed secondary postoperative haemorrhage).
Interpretation of Standard Coagulation Profiles
Prothrombin Time (PT / INR): Measures the extrinsic (Factor VII) and common pathways (Factors X, V, II [prothrombin], I [fibrinogen]). Prolonged by warfarin , vitamin K deficiency, liver failure, and DIC.
Activated Partial Thromboplastin Time (APTT): Measures the intrinsic (Factors XII, XI, IX, VIII) and common pathways (Factors X, V, II, I). Prolonged by unfractionated heparin , haemophilia A (VIII) and B (IX) , von Willebrand disease (variable/mild), and lupus anticoagulant (paradoxical in vitro artefact; prothrombotic in vivo).
Fibrinogen / Thrombin Time (TT): Evaluates the conversion of fibrinogen to fibrin. Depleted in severe DIC, massive haemorrhage, and severe hepatic synthesis failure; inhibited by dabigatran and direct thrombin inhibitors.
- 2. Inherited Bleeding Disorders
- Haemophilia A & B
Haemophilia A: Deficiency or functional absence of Factor VIII . Inherited as an X-linked recessive trait (~85% of all haemophilia cases; predominantly affects males; females are typically asymptomatic obligate or facultative carriers).
Haemophilia B (Christmas Disease): Deficiency or functional absence of Factor IX . Also inherited as an X-linked recessive trait (~15% of cases). Clinically indistinguishable from Haemophilia A.
Clinical Features: Deep, painful, recurrent bleeding episodes into large synovial joints ( haemarthroses , most commonly knees, elbows, and ankles), leading to chronic hypertrophic synovitis and crippling fixed joint arthropathy. Large intramuscular haematomas occur after minimal trauma. Superficial cuts and mucosal bleeding are characteristically absent.
Coagulation Profile: Isolated, significantly prolonged APTT with a completely normal PT, normal platelet count, and normal bleeding time / vWF profile.
Management:
Definitive Therapy: Prompt intravenous administration of recombinant Factor VIII (for Haemophilia A) or recombinant Factor IX (for Haemophilia B) concentrates.
Mild Haemophilia A: Intravenous or intranasal Desmopressin (DDAVP) stimulates the exocytosis of endogenous Factor VIII and vWF from endothelial Weibel-Palade bodies, temporarily raising circulating FVIII levels 2- to 4-fold.
Precautions: Strictly avoid intramuscular injections, non-steroidal anti-inflammatory drugs (NSAIDs), and aspirin. Maintain regular prophylactic factor infusions in severe disease (factor level <1%).
von Willebrand Disease (vWD)
Pathophysiology: The most common inherited bleeding disorder , affecting approximately 1% of the population. Characterised by quantitative or qualitative deficiencies in von Willebrand factor (vWF). Inherited predominantly as an autosomal dominant trait (Types 1 and 2; Type 3 is autosomal recessive and severe).
Dual Functions of vWF:
Binds platelets to subendothelial collagen at sites of vascular shear stress (primary haemostasis).
Acts as the protective circulating carrier chaperone protein for Factor VIII , preventing its rapid proteolytic degradation by activated protein C.
Clinical Presentation: Defective primary haemostasis: recurrent epistaxis, easy spontaneous bruising, heavy menstrual bleeding ( menorrhagia in adolescent and adult females), prolonged oozing after dental extractions or minor cutaneous lacerations.
Laboratory Profile: Bleeding time / platelet function analyser (PFA-100) is prolonged. APTT is normal or mildly prolonged (secondary to reduced FVIII levels). PT and platelet counts are normal (except in rare Type 2B vWD where platelet count is low).
Management:
Antifibrinolytic agents (oral or IV tranexamic acid ) for minor dental or mucosal bleeding.
Desmopressin (DDAVP): Highly effective in Type 1 vWD to release stored endothelial vWF pools.
Severe bleeding or Type 2/3 vWD: Plasma-derived or recombinant vWF-containing Factor VIII concentrates (e.g. Haemate P).
- 3. Acquired Platelet & Consumptive Disorders
- Immune Thrombocytopenia (ITP)
Pathophysiology: Acquired autoimmune disorder characterised by circulating IgG autoantibodies directed against platelet membrane glycoproteins (GpIIb/IIIa). Antibody-coated platelets undergo premature destruction by Fc-receptor mediated phagocytosis within splenic macrophages.
Clinical Presentation: Isolated thrombocytopenia manifesting as petechiae, spontaneous purpura, gingival bleeding, or epistaxis in an otherwise systemically well patient. Splenomegaly is notably absent; presence of lymphadenopathy or splenomegaly should prompt search for leukaemia or lymphoma.
Laboratory Profile: Isolated severe thrombocytopenia (<50 x 10^9/L; often <20 x 10^9/L). Coagulation screen (PT, APTT, fibrinogen) and peripheral blood film red/white cell morphology are entirely normal.
Management:
Mild/Asymptomatic: Platelets >30 x 10^9/L without bleeding: observation and outpatient monitoring.
First-Line Active Therapy: Oral prednisolone (1 mg/kg/day) tapered over several weeks, OR Intravenous Immunoglobulin (IVIG) (preferred when a rapid platelet rise is mandated for active haemorrhage or emergency surgery).
Second-Line: Thrombopoietin receptor agonists (Eltrombopag, Romiplostim), Rituximab, or Laparoscopic Splenectomy.
Thrombotic Thrombocytopenic Purpura (TTP)
Pathophysiology: A life-threatening thrombotic microangiopathy caused by severe functional deficiency of the ADAMTS13 metalloprotease (<10% activity), most commonly secondary to acquired IgG autoantibodies. ADAMTS13 is responsible for cleaving ultra-large vWF multimers into smaller physiological units. In its absence, uncleaved ultra-large vWF multimers bind platelets spontaneously, generating widespread platelet-rich microvascular thrombi that shear circulating erythrocytes and cause end-organ ischaemia.
The Classic Pentad of TTP:
Microangiopathic Haemolytic Anaemia (MAHA): Jaundice, elevated LDH, undetectable haptoglobin, and prominent schistocytes ("helmet cells") on blood film.
Severe Thrombocytopenia: Petechiae, purpura, bruising.
Neurological Fluctuations: Transient ischaemic attacks, fluctuating confusion, headache, visual changes, seizures, or coma.
Renal Dysfunction: Proteinuria, microscopic haematuria, acute kidney injury (usually milder than in HUS).
Fever: Mild pyrexia.
Caution
TTP Medical Emergency & Platelet Transfusion Contraindication: TTP carries a >90% mortality if untreated. Platelet transfusions are strictly contraindicated because transfusing platelets provides substrate that "fuels the fire" of microvascular thrombosis, triggering catastrophic strokes and myocardial infarction. The definitive life-saving therapy is emergency Plasma Exchange (PEX) with fresh frozen plasma to clear autoantibodies and replenish ADAMTS13, combined with high-dose corticosteroids and the anti-vWF nanobody Caplacizumab .
Disseminated Intravascular Coagulation (DIC)
Etiology: Systemic activation of coagulation cascades secondary to overwhelming underlying pathology: Gram-negative sepsis (endotoxin), severe trauma/burns, obstetric catastrophes (placental abruption, amniotic fluid embolism), or malignancy (APML, adenocarcinoma).
Pathology: Massive intravascular thrombin generation causes microvascular thrombosis and end-organ failure, accompanied by consumption and exhaustion of platelets, fibrinogen, and clotting factors (consumptive coagulopathy), driving uncontrolled catastrophic systemic haemorrhage.
Diagnostic Profile: Prolonged PT and APTT , severe thrombocytopenia , profoundly depleted fibrinogen (<1.5 g/L) , and markedly elevated D-dimer / FDPs .
Management: Treat the underlying precipitant aggressively (antibiotics, delivery, surgical control). Provide supportive replacement: platelets (maintain >50 x 10^9/L), fresh frozen plasma (FFP for prolonged PT/APTT), and cryoprecipitate (to maintain fibrinogen >1.5 g/L).
Feature Haemophilia A von Willebrand Disease ITP TTP DIC
Primary Defect Factor VIII deficiency vWF deficiency / defect Anti-platelet autoantibodies ADAMTS13 deficiency Massive thrombin activation
Inheritance X-linked recessive Autosomal dominant Acquired autoimmune Acquired (or congenital) Acquired systemic response
Bleeding Type Haemarthroses, haematomas Mucocutaneous, menorrhagia Petechiae, purpura Petechiae, purpura Simultaneous thrombosis & oozing
- Platelet Count Normal Normal (rarely low) Markedly Low Markedly Low Markedly Low
- PT / INR Normal Normal Normal Normal Prolonged
- APTT Prolonged Normal or Prolonged Normal Normal Prolonged
- Fibrinogen Normal Normal Normal Normal Markedly Depleted
- Blood Film Normal Normal Isolated low platelets Schistocytes (MAHA) Schistocytes
- 4. Anticoagulant Monitoring & Emergency Reversal Protocols
- Warfarin (Vitamin K Antagonist)
Warfarin competitively inhibits Vitamin K Epoxide Reductase Complex 1 (VKORC1), blocking gamma-carboxylation of clotting factors II, VII, IX, and X , as well as natural anticoagulants Protein C and Protein S .
Monitoring: Monitored via the International Normalised Ratio (INR) . Target INR is 2.5 (2.0–3.0) for venous thromboembolism (DVT, PE) and non-valvular atrial fibrillation; target is 3.5 (3.0–4.0) for mechanical mitral prosthetic heart valves.
Emergency Reversal Protocols (NICE / BCSH Guidelines):
Major Life-Threatening Bleeding (Intracranial, Massive GI, Retroperitoneal):
Stop Warfarin immediately .
Administer Four-Factor Prothrombin Complex Concentrate (4F-PCC) (e.g. Beriplex, Octaplex; contains concentrated factors II, VII, IX, X) at a dose of 25–50 IU/kg IV infusion . Reverses anticoagulation completely within 10–15 minutes.
Co-administer Intravenous Phytomenadione (Vitamin K1) 5–10 mg slow IV (takes 4–6 hours to stimulate de novo hepatic factor synthesis, ensuring sustained reversal once PCC factors are cleared).
Note: Fresh Frozen Plasma (FFP) is slow to infuse, requires ABO matching, risks fluid overload, and is only used if 4F-PCC is unavailable .
Minor Bleeding with INR >5.0: Stop warfarin, give slow IV vitamin K (phytomenadione) 1–3 mg , and restart warfarin when INR is below 5.0.
No Bleeding with INR >8.0: Stop warfarin, administer oral Vitamin K 1–5 mg , review INR in 24 hours.
No Bleeding with INR 5.0–8.0: Withhold 1–2 doses of warfarin, reduce maintenance dose, monitor INR.
Direct Oral Anticoagulants (DOACs)
Direct Thrombin Inhibitor: Dabigatran (Pradaxa):
Directly inhibits free and clot-bound thrombin (Factor IIa).
Specific Reversal Agent: Idarucizumab (Praxbind) , a humanized monoclonal antibody fragment that binds dabigatran with 350-fold higher affinity than thrombin. Administered as 5 g IV (2 x 2.5 g vials infused consecutively) ; achieves immediate complete reversal.
Direct Factor Xa Inhibitors: Apixaban, Rivaroxaban, Edoxaban:
Directly inhibit free and bound Factor Xa.
Specific Reversal Agent: Andexanet alfa (Ondexxya) , a recombinant modified decoy Factor Xa protein that sequesters Xa inhibitors. Where Andexanet alfa is unavailable or non-formulary, administer 4-factor PCC (25–50 IU/kg IV) .
Heparin Reversal
Unfractionated Heparin (UFH): Monitored by APTT ratio (target 1.5–2.5). Reversed completely by Protamine Sulfate (1 mg protamine neutralizes 100 units of UFH; maximum single dose 50 mg slow IV to prevent anaphylactoid hypotension and bradycardia).
Low Molecular Weight Heparin (LMWH: Enoxaparin, Dalteparin): Protamine sulfate provides only partial reversal (~60%) due to poor binding to shorter polysaccharide chains.